← Eichor
Condition: Patients With Advanced Solid Tumors Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Patients With Advanced Solid Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid Tumors
Phase 1 · 1 location(s) · Shanghai Pudong Hospital · NCT06501183A Study of TIL in Advanced Solid Tumors (DFGD)
EARLY_Phase 1 · 1 location(s) · Shanghai Juncell Therapeutics · NCT06488950A Study of CM350 in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 2 location(s) · Keymed Biosciences Co.Ltd · NCT05263960A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
Phase 1/Phase 2 · 1 location(s) · CytosinLab Therapeutics Co., Ltd. · NCT06971523A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
Phase 1/Phase 2 · 4 location(s) · Latticon Antibody Therapeutics, Inc · NCT06277219A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.
Phase 1 · 6 location(s) · Shanghai Pharmaceuticals Holding Co., Ltd · NCT06487455CW-301 FIH Study of CAN016
Phase 1/Phase 2 · 1 location(s) · Canwell Biotech Limited · NCT07664150A Study of WX390 in Patients With Advanced Solid Tumors
Phase 2 · 1 location(s) · Shanghai Jiatan Pharmatech Co., Ltd · NCT06117540SKB445 for Injection in Solid Tumors
Phase 1 · 1 location(s) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · NCT06826040HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT05681650Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Phase 1 · 7 location(s) · Novartis Pharmaceuticals · NCT07006727Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unrese
Phase 1 · 4 location(s) · National Cancer Institute (NCI) · NCT05111561Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metas
Phase 1 · 5 location(s) · Kiromic BioPharma Inc. · NCT06069570EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)
Phase 1/Phase 2 · 29 location(s) · Grey Wolf Therapeutics · NCT06923761a Single-arm, Single-center, Open Clinical Study
Phase N/A · 1 location(s) · Beijing Geekgene Technology Co., LTD · NCT06431100A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
Phase 1 · 37 location(s) · Aurigene Discovery Technologies Limited · NCT05865002A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）
Phase 1 · 1 location(s) · L & L Bio Co., Ltd., Ningbo, China · NCT05357651A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
Phase 1/Phase 2 · 9 location(s) · NuCana plc · NCT03829254A Study of HS-20122 in Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · Hansoh BioMedical R&D Company · NCT06927570A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
Phase 1 · 19 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT06859762APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Phase 1/Phase 2 · 3 location(s) · Ascentage Pharma Group Inc. · NCT04785196An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced
Phase 1 · 3 location(s) · Shenzhen Ionova Life Sciences Co., Ltd. · NCT04443088A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07298772A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients
Phase 1 · 41 location(s) · Genentech, Inc. · NCT06619587A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Xuanzhu Biopharmaceutical Co., Ltd. · NCT04996121Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
Phase 1 · 9 location(s) · Oncomatryx Biopharma S.L. · NCT05547321A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 24 location(s) · Beijing InnoCare Pharma Tech Co., Ltd. · NCT04685226A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations
Phase 1/Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06947811A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and
Phase 1 · 9 location(s) · Boehringer Ingelheim · NCT07607678Trial of DFP-14927 in Advanced Solid Tumors
Phase 1 · 2 location(s) · Delta-Fly Pharma, Inc. · NCT03943004
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.